Business Context and Reporting Period
This Form 8-K was filed by ADVENTRX Pharmaceuticals, Inc. on February 28, 2013. The filing reports a corporate name change and strategic updates effective March 11, 2013.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and strategic events rather than financial performance.
Material Changes
- Corporate Name Change: The Company merged with its wholly-owned subsidiary, Mast Therapeutics, Inc., to adopt the new legal name "Mast Therapeutics, Inc."
- Stock Ticker: Common stock will trade under the new ticker symbol "MSTX" on the NYSE MKT starting March 11, 2013.
- CUSIP Numbers: New CUSIP numbers were assigned: 576314 108 for common stock and 576314 116 for common stock purchase warrants issued in November 2011.
- Bylaws: Amended and Restated Bylaws reflecting the name change became effective March 11, 2013.
Guidance, Outlook, and Management Commentary
Management announced plans to develop ANX-188, the Company's lead product candidate, for complications of arterial disease. The initial focus is on acute limb ischemia as an adjunct to thrombolytics. No specific financial guidance or risk factors were detailed in this specific filing.
Investor Verification Checklist
- Verify the effective date of the name change and ticker symbol switch (March 11, 2013).
- Confirm that existing stock certificates and warrants remain valid and do not require exchange.
- Review the attached press releases (Exhibits 99.1 and 99.2) for details on the ANX-188 development strategy.
- Check the new CUSIP numbers for trading and settlement purposes.